518044-32-1

基本信息
丙酸叔丁酯-四聚乙二醇
四聚乙二醇-丙酸叔丁酯
羥基-PEG4-叔丁酯
羥基-四乙二醇-丙酸叔丁酯
羥基四聚乙二醇纈氨酸叔丁酯
羥基-四聚乙二醇-丙酸叔丁酯
丙酸叔丁酯-四聚乙二醇 1G
1-羥基-3,6,9,12-四氧雜十五烷酸叔丁酯
1-羥基-3,6,9,12-四氧雜十五烷-15-酸叔丁酯
518044-32-1
HO-PEG4-COOtBu
PEG5-t-butly ester
HO-PEG4-CH2CH2COOTBU
OH-PEG4-CH2CH2COOtBu
Hydroxy-PEG4-(CH2)2-Boc
HO-PEG4 tert-Butyl Ester
Hydroxy-PEG4-t-butly ester
tert-Butyl PEG4 propanoate
物理化學(xué)性質(zhì)
制備方法

112-60-7

1663-39-4

518044-32-1
一般步驟:向三縮四乙二醇(40.61 mL; 45.64 g; 235 mmol)的無(wú)水四氫呋喃(THF,125 mL)溶液中加入一片鈉(約1/4 cm)。待鈉完全反應(yīng)后,在20分鐘內(nèi)逐滴加入丙烯酸叔丁酯(11.98 mL; 10.57 g; 82.5 mmol),并將反應(yīng)混合物在室溫下攪拌過(guò)夜。反應(yīng)完成后,用1N NaOH溶液調(diào)節(jié)pH至7-8,隨后在減壓下除去溶劑。將殘余物溶解于飽和NaHCO3和NaCl混合溶液(75 mL)中,并用乙酸乙酯(EtOAc,3×100 mL)萃取。合并有機(jī)層,用無(wú)水硫酸鎂(MgSO4)干燥,過(guò)濾后減壓蒸發(fā)溶劑,得到叔丁基-15-羥基-4,7,10,13-四氧雜十五烷酸酯(21.87 g; 67.8 mmol; 產(chǎn)率82%,基于丙烯酸叔丁酯計(jì)算),為無(wú)色油狀物。產(chǎn)物經(jīng)1H-NMR(500 MHz, CDCl3, TMS)和13C{1H}-NMR(126 MHz, CDCl3, TMS)表征,數(shù)據(jù)如下:1H-NMR δ [ppm] = 3.77-3.57 (m, 18H, OCH2); 3.01 (bs, 1H, OH); 2.51 (t, 2H, J = 6.6 Hz, CH2COO'Bu); 1.45 (s, 9H, C(CH3)3); 13C{1H}-NMR δ [ppm] = 171.1 (COO); 80.7 (C(CH3)3); 72.6 / 70.8 / 70.7 / 70.6 / 70.5 / 67.0 (OCH2); 61.9 (HOCH2); 36.4 (CH2CO); 28.2 (C(CH3)3)。
參考文獻(xiàn):
[1] Synthetic Communications, 2004, vol. 34, # 13, p. 2425 - 2432
[2] Patent: WO2016/146638, 2016, A1. Location in patent: Page/Page column 20
[3] Patent: WO2017/147542, 2017, A2. Location in patent: Paragraph 00162
[4] Patent: WO2018/89373, 2018, A2. Location in patent: Paragraph 0638-0639
[5] Tetrahedron, 2011, vol. 67, # 12, p. 2251 - 2259
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2025/05/22 | HY-W039178 | 丙酸叔丁酯-四聚乙二醇 Hydroxy-PEG4-(CH2)2-Boc | 518044-32-1 | 1 g | 185元 |
2025/05/22 | HY-W039178 | 丙酸叔丁酯-四聚乙二醇 Hydroxy-PEG4-(CH2)2-Boc | 518044-32-1 | 5 g | 740元 |
2025/05/22 | HY-W039178 | 丙酸叔丁酯-四聚乙二醇 Hydroxy-PEG4-(CH2)2-Boc | 518044-32-1 | 10 g | 1335元 |
常見(jiàn)問(wèn)題列表
Non-cleavable
|
Alkyl/ether
|
PEGs
|
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.